Westfield Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-165,107
| Closed | -$50M | – | 256 |
|
|
2025
Q4 | $50M | Buy |
165,107
+9,583
| +6% | +$2.99M | 0.21% | 149 |
|
|
2025
Q3 | $43.6M | Buy |
155,524
+16,019
| +11% | +$4.36M | 0.18% | 158 |
|
|
2025
Q2 | $33.7M | Buy |
139,505
+4,834
| +4% | +$1.14M | 0.14% | 173 |
|
|
2025
Q1 | $32.8M | Sell |
134,671
-129,934
| -49% | -$39.1M | 0.16% | 160 |
|
|
2024
Q4 | $86.9M | Buy |
264,605
+11,836
| +5% | +$4.02M | 0.38% | 77 |
|
|
2024
Q3 | $84.6M | Buy |
252,769
+9,584
| +4% | +$3.04M | 0.38% | 82 |
|
|
2024
Q2 | $66.4M | Buy |
243,185
+12,676
| +5% | +$3.69M | 0.33% | 100 |
|
|
2024
Q1 | $79.7M | Sell |
230,509
-16,701
| -7% | -$5.49M | 0.42% | 86 |
|
|
2023
Q4 | $79.8M | Sell |
247,210
-115,118
| -32% | -$36.1M | 0.47% | 77 |
|
|
2023
Q3 | $130M | Sell |
362,328
-41,484
| -10% | -$16M | 0.88% | 25 |
|
|
2023
Q2 | $153M | Buy |
403,812
+18,156
| +5% | +$7.39M | 0.97% | 22 |
|
|
2023
Q1 | $185M | Sell |
385,656
-3,848
| -1% | -$1.8M | 1.31% | 11 |
|
|
2022
Q4 | $164M | Buy |
389,504
+28,389
| +8% | +$11.5M | 1.26% | 14 |
|
|
2022
Q3 | $151M | Buy |
361,115
+927
| +0.3% | +$462K | 1.2% | 13 |
|
|
2022
Q2 | $178M | Buy |
360,188
+18,356
| +5% | +$9.56M | 1.4% | 10 |
|
|
2022
Q1 | $193M | Buy |
341,832
+10,113
| +3% | +$6.1M | 1.23% | 13 |
|
|
2021
Q4 | $251M | Sell |
331,719
-17,964
| -5% | -$13.4M | 1.49% | 8 |
|
|
2021
Q3 | $261M | Sell |
349,683
-56,589
| -14% | -$42.4M | 1.57% | 8 |
|
|
2021
Q2 | $262M | Buy |
406,272
+1,805
| +0.4% | +$1.1M | 1.57% | 9 |
|
|
2021
Q1 | $231M | Sell |
404,467
-7,595
| -2% | -$4.5M | 1.44% | 10 |
|
|
2020
Q4 | $240M | Buy |
412,062
+114,029
| +38% | +$64.9M | 1.43% | 10 |
|
|
2020
Q3 | $154M | Sell |
298,033
-57,337
| -16% | -$29M | 0.99% | 21 |
|
|
2020
Q2 | $160M | Sell |
355,370
-34,528
| -9% | -$15.2M | 1.1% | 18 |
|
|
2020
Q1 | $137M | Sell |
389,898
-70,731
| -15% | -$26M | 1.2% | 18 |
|
|
2019
Q4 | $170M | Buy |
460,629
+48,717
| +12% | +$17.2M | 1.21% | 16 |
|
|
2019
Q3 | $137M | Buy |
411,912
+52,300
| +15% | +$17.1M | 1.1% | 21 |
|
|
2019
Q2 | $112M | Sell |
359,612
-16,859
| -4% | -$5.05M | 0.85% | 32 |
|
|
2019
Q1 | $115M | Buy |
376,471
+453
| +0.1% | +$122K | 0.88% | 30 |
|
|
2018
Q4 | $87.3M | Buy |
376,018
+29,265
| +8% | +$7.85M | 0.74% | 46 |
|
|
2018
Q3 | $109M | Buy |
346,753
+85,191
| +33% | +$26.4M | 0.76% | 34 |
|
|
2018
Q2 | $75.5M | Buy |
261,562
+13,118
| +5% | +$3.62M | 0.56% | 57 |
|
|
2018
Q1 | $62.1M | Buy |
248,444
+99,401
| +67% | +$25.3M | 0.48% | 74 |
|
|
2017
Q4 | $35.6M | Buy |
149,043
+49,255
| +49% | +$11.9M | 0.27% | 139 |
|
|
2017
Q3 | $22.2M | Buy |
+99,788
| New | +$22.5M | 0.17% | 177 |
|
Other funds holding BIO
AI
Westfield Capital Management's BIO Position: Q1 2026 in Review
Westfield Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 165,107 shares — an estimated $50M sold.
Westfield Capital Management first reported a position in BIO in Q3 2017 and held it in 34 quarters. The position peaked at $262M in Q2 2021. 393 funds tracked by Wall St. Rank hold BIO as of Q1 2026.
- Westfield Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
- Westfield Capital Management sold 165,107 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $50M.
- Westfield Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2017 and held it in 34 quarters.
- Westfield Capital Management's Bio-Rad Laboratories Class A position peaked at $262M in Q2 2021.
- 393 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.
Based on Westfield Capital Management's 13F filing for Q1 2026, filed 11 May 2026.